• LevelJump will issue up to 16,666,667 units at $0.15 per unit for gross proceeds of up to $2,500,000
  • Net proceeds from the financing will be used towards acquisitions and for general working capital purposes
  • The offering is expected to close in late January
  • Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology
  • Shares in Leveljump Healthcare Corp. (JUMP) are down 4.76 per cent on the day, trading at C$0.10 per share at 12:30 pm EST

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $2,500,000.

The company will issue up to 16,666,667 units at $0.15 per unit. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share of Leveljump at an exercise price of $0.20 with an expiry date of January 31, 2024.

The net proceeds from the financing will be used towards acquisitions and for general working capital purposes.

The offering is expected to close in late January.

Securities issued will be subject to a four-month hold period in accordance with applicable securities laws.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The company provides radiology solutions for hospitals, emergency rooms, and private clinics.

Shares in Leveljump Healthcare Corp. (JUMP) are down 4.76 per cent on the day, trading at C$0.10 per share at 12:30 pm EST.

More From The Market Online

Buzz on the Bullboards: Oil shock, biotech breakthroughs and new tech

Global equities lurched from rally to rout since the U.S.–Israel strikes on Iran ignited a regional war and shutdown of the Strait of Hormuz.

Quit smoking with psychedelics? A new frontier for treatment — and investors

A new Johns Hopkins study found that a single dose of psilocybin, combined with therapy, helped smokers stay cigarette free at six months.

New bladder cancer drug may sharpen radiation’s aim

Theralase Technologies proves that its Rutherrin drug holds the potential to enhance radiation against non-muscle invasive bladder cancer.